HCV NS5B Polymerase Inhibitors

被引：49

作者：

Burton, James R., Jr. ^{[1
]}

Everson, Gregory T. ^{[1
]}

机构：

[1] Univ Colorado Denver, Div Gastroenterol & Hepatol, Dept Med, Aurora, CO 80045 USA

来源：

CLINICS IN LIVER DISEASE | 2009年 / 13卷 / 03期

关键词：

Hepatitis C; Polymerase inhibitors; Antiviral therapy; Clinical trials; Nucleoside analog; Non-nucleoside analog; HEPATITIS-C VIRUS; ALPHA-2A PLUS RIBAVIRIN; ANTIVIRAL ACTIVITY; PEGINTERFERON ALPHA-2A; IN-VITRO; PEG-IFN; NUCLEOSIDE ANALOG; POTENT INHIBITOR; SAFETY; R7128;

D O I：

10.1016/j.cld.2009.05.001

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Chronic hepatitis C virus (HCV) infection affects approximately 4 million persons and is the major indication for liver transplantation in the United States. The current standard for treatment of HCV is pegylated interferon in combination with ribavirin. Despite significant advances in treatment, only approximately 50% of patients of treated patients clear HCV infection. Polymerase inhibitors, given their potent antiviral effects, represent a major contribution to the future of HCV treatment. Whether these new drugs will have a role in the treatment of the difficult patient (non-responders, those co-infected with HIV, decompensated liver disease and liver transplant recipients) remains to be determined.

引用

页码：453 / +

页数：14

共 37 条

[1] Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to pegIFN/RBV: One-year results [J].

Afdhal, N. ;

O'Brien, C. ;

Godofsky, E. ;

Rodriguez-Torres, M. ;

Pappas, S. C. ;

Lawitz, E. ;

Pockros, P. ;

Sulkowski, M. ;

Jacobson, I. ;

Chao, G. ;

Knox, S. ;

Pietropaolo, K. ;

Brown, N. A. .

JOURNAL OF HEPATOLOGY, 2007, 46 :S5-S5

[2] National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002 [J].

不详 .

HEPATOLOGY, 2002, 36 (05) :S3-S20

[3]

Bavisotto L, 2007, HEPATOLOGY, V46, p255A

[4] Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees [J].

Carroll, Steven S. ;

Ludmerer, Steven ;

Handt, Larry ;

Koeplinger, Kenneth ;

Zhang, Nanyan Rena ;

Graham, Donald ;

Davies, Mary-Ellen ;

MacCoss, Malcolm ;

Hazuda, Daria ;

Olsen, David B. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) :926-934

[5] Safety and pharmacokinetics of the nonnucleoside polymerase inhibitor, HCV-796: Results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects [J].

Chandra, P. ;

Raible, D. ;

Moyer, L. ;

Harper, D. ;

Speth, J. ;

Villano, S. ;

Fruncillo, R. .

JOURNAL OF HEPATOLOGY, 2006, 44 :S208-S209

[6] Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons [J].

Chung, RT ;

Andersen, J ;

Volberding, P ;

Robbins, GK ;

Liu, T ;

Sherman, KE ;

Peters, MG ;

Koziel, MJ ;

Bhan, AK ;

Alston, B ;

Colquhoun, D ;

Nevin, T ;

Harb, G ;

van der Horst, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :451-459

[7] Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 [J].

Conjeevaram, Hari S. ;

Fried, Michael W. ;

Jeffers, Lennox J. ;

Terrault, Norah A. ;

Wiley-Lucas, Thelma E. ;

Afdhal, Nezam ;

Brown, Robert S. ;

Belle, Steven H. ;

Hoofnagle, Jay H. ;

Kleiner, David E. ;

Howell, Charles D. .

GASTROENTEROLOGY, 2006, 131 (02) :470-477

[8]

Cooper C, 2007, HEPATOLOGY, V46, p864A

[9] In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication [J].

Cretton-Scott, E. ;

Perigaud, C. ;

Peyrottes, S. ;

Licklider, L. ;

Camire, M. ;

Larsson, M. ;

La Colla, M. ;

Hildebrand, E. ;

Lallos, L. ;

Bilello, J. ;

McCarville, J. ;

Seifer, M. ;

Liuzzi, M. ;

Pierra, C. ;

Badaroux, E. ;

Gosselin, G. ;

Surleraux, D. ;

Standring, D. N. .

JOURNAL OF HEPATOLOGY, 2008, 48 :S220-S220

[10] Safety, pharmacokinetics and antiviral effect of BILB1941, a novel HCVRNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C [J].

Erhardt, A. ;

Wedemeyer, H. ;

Benhamou, Y. ;

Moellekens, C. ;

Foms, X. ;

Pol, S. ;

Calleja, J. L. ;

Ross, S. ;

Spangenberg, H. C. ;

Garcia-Samaniego, J. ;

Fuchs, M. ;

Enriquezo, J. ;

Wiegand, J. ;

Stern, J. ;

Wu, K. ;

Nehmiz, G. ;

Stefilgen, J. .

JOURNAL OF HEPATOLOGY, 2007, 46 :S222-S222

← 1 2 3 4 →